(PRM) Perimeter Solutions - Overview
Sector: Basic MaterialsIndustry: Specialty Chemicals | Exchange NYSE (USA) | Currency USD | Market Cap: 3.150m | Total Return 100.9% in 12m
Stock: Fire Retardants, Foams, Lubricant Additives, Machinery, Batteries
| Risk 5d forecast | |
|---|---|
| Volatility | 47.6% |
| Relative Tail Risk | -11.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.64 |
| Alpha | 98.18 |
| Character TTM | |
|---|---|
| Beta | 1.234 |
| Beta Downside | 0.674 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.86% |
| CAGR/Max DD | 0.61 |
EPS (Earnings per Share)
Revenue
Description: PRM Perimeter Solutions March 05, 2026
Perimeter Solutions, Inc. (PRM) manufactures and supplies firefighting products, electronic components, lubricant additives, and engineered machinery globally.
The company operates through two segments. The Fire Safety segment provides fire retardants, firefighting foams, and related equipment and services. This segment serves government and commercial clients. The firefighting chemicals market is a niche but critical sector for disaster management.
The Specialty Products segment focuses on non-fire safety markets. It produces phosphorus pentasulfide-based lubricant additives used in pesticide and mining chemicals, and electric battery technologies. This segment also offers engineered machinery, aftermarket parts, and automation solutions for medical devices. The medical device manufacturing sector is characterized by high precision and stringent regulatory requirements.
Perimeter Solutions was founded in 1963 and is headquartered in Clayton, Missouri. For further in-depth analysis, consider exploring ValueRays comprehensive reports.
Headlines to watch out for
- Wildfire season severity impacts fire retardant demand
- Industrial lubricant additive sales tied to manufacturing output
- Global mining activity influences phosphorus pentasulfide demand
- Medical device manufacturing growth boosts engineered machinery sales
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -206.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.37 > 1.0 |
| NWC/Revenue: 59.56% < 20% (prev 59.10%; Δ 0.46% < -1%) |
| CFO/TA 0.09 > 3% & CFO 244.8m > Net Income -206.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.8m) vs 12m ago -7.53% < -2% |
| Gross Margin: 57.46% > 18% (prev 0.57%; Δ 5.69k% > 0.5%) |
| Asset Turnover: 25.76% > 50% (prev 23.22%; Δ 2.54% > 0%) |
| Interest Coverage Ratio: -5.10 > 6 (EBITDA TTM -140.0m / Interest Expense TTM 39.1m) |
Altman Z'' -1.09
| A: 0.15 (Total Current Assets 564.0m - Total Current Liabilities 175.1m) / Total Assets 2.65b |
| B: -0.30 (Retained Earnings -793.1m / Total Assets 2.65b) |
| C: -0.08 (EBIT TTM -199.4m / Avg Total Assets 2.53b) |
| D: -0.53 (Book Value of Equity -799.4m / Total Liabilities 1.52b) |
| Altman-Z'' Score: -1.09 = CCC |
Beneish M -3.29
| DSRI: 0.82 (Receivables 64.4m/67.1m, Revenue 652.9m/561.0m) |
| GMI: 0.98 (GM 57.46% / 56.52%) |
| AQI: 0.93 (AQ_t 0.74 / AQ_t-1 0.80) |
| SGI: 1.16 (Revenue 652.9m / 561.0m) |
| TATA: -0.17 (NI -206.4m - CFO 244.8m) / TA 2.65b) |
| Beneish M-Score: -3.29 (Cap -4..+1) = AA |
What is the price of PRM shares?
Over the past week, the price has changed by +3.14%, over one month by -9.11%, over three months by -24.14% and over the past year by +100.94%.
Is PRM a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PRM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.5 | 42.9% |
| Analysts Target Price | 30.5 | 42.9% |
PRM Fundamental Data Overview March 25, 2026
P/S = 4.8252
P/B = 2.7282
Revenue TTM = 652.9m USD
EBIT TTM = -199.4m USD
EBITDA TTM = -140.0m USD
Long Term Debt = 669.1m USD (from longTermDebt, last quarter)
Short Term Debt = 4.42m USD (from shortTermDebt, two quarters ago)
Debt = 819.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 493.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.64b USD (3.15b + Debt 819.9m - CCE 325.9m)
Interest Coverage Ratio = -5.10 (Ebit TTM -199.4m / Interest Expense TTM 39.1m)
EV/FCF = 18.25x (Enterprise Value 3.64b / FCF TTM 199.7m)
FCF Yield = 5.48% (FCF TTM 199.7m / Enterprise Value 3.64b)
FCF Margin = 30.59% (FCF TTM 199.7m / Revenue TTM 652.9m)
Net Margin = -31.61% (Net Income TTM -206.4m / Revenue TTM 652.9m)
Gross Margin = 57.46% ((Revenue TTM 652.9m - Cost of Revenue TTM 277.7m) / Revenue TTM)
Gross Margin QoQ = 59.94% (prev 58.30%)
Tobins Q-Ratio = 1.37 (Enterprise Value 3.64b / Total Assets 2.65b)
Interest Expense / Debt = 1.18% (Interest Expense 9.69m / Debt 819.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -157.5m (EBIT -199.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.22 (Total Current Assets 564.0m / Total Current Liabilities 175.1m)
Debt / Equity = 0.72 (Debt 819.9m / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = -3.53 (negative EBITDA) (Net Debt 493.9m / EBITDA -140.0m)
Debt / FCF = 2.47 (Net Debt 493.9m / FCF TTM 199.7m)
Total Stockholder Equity = 1.16b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.14% (Net Income -206.4m / Total Assets 2.65b)
RoE = -17.79% (Net Income TTM -206.4m / Total Stockholder Equity 1.16b)
RoCE = -10.90% (EBIT -199.4m / Capital Employed (Equity 1.16b + L.T.Debt 669.1m))
RoIC = -8.62% (negative operating profit) (NOPAT -157.5m / Invested Capital 1.83b)
WACC = 8.38% (E(3.15b)/V(3.97b) * Re(10.32%) + D(819.9m)/V(3.97b) * Rd(1.18%) * (1-Tc(0.21)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.67%
[DCF] Terminal Value 77.05% ; FCFF base≈189.0m ; Y1≈188.7m ; Y5≈199.5m
[DCF] Fair Price = 18.87 (EV 3.31b - Net Debt 493.9m = Equity 2.82b / Shares 149.4m; r=8.38% [WACC]; 5y FCF grow -0.78% → 3.0% )
EPS Correlation: 19.95 | EPS CAGR: 7.52% | SUE: 0.42 | # QB: 0
Revenue Correlation: 45.72 | Revenue CAGR: 16.60% | SUE: 0.32 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.38 | Chg7d=+0.035 | Chg30d=+0.035 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=1.33 | Chg7d=+0.070 | Chg30d=+0.070 | Revisions Net=+1 | Growth EPS=-1.1% | Growth Revenue=+26.9%
EPS next Year (2027-12-31): EPS=1.47 | Chg7d=+0.081 | Chg30d=+0.081 | Revisions Net=+1 | Growth EPS=+10.8% | Growth Revenue=+6.6%